Inhibition of protein kinase C-α isoform enhances the P-glycoprotein expression and the survival of LoVo human colon adenocarcinoma cells to doxorubicin exposure

CAM La Porta1,3, E Dolfini2 and R Comolli1,3

1Department of General Physiology and Biochemistry, Section of General Pathology; 2Department of Biology and Genetics for Health Science, University of Milan; and 3CNR Center for Research in Cell Pathology, Milan, Italy

Summary The aim of the present paper was to analyse the effect of long-term inhibitory treatment, for at least 7 days, of individual protein kinase C (PKC) isoforms on the survival of LoVo human colon adenocarcinoma cells to doxorubicin exposure. The treatment for 2 h, after plating the cells, and after 3 days with 1 μM Gö6976, a specific inhibitor of protein kinase C (PKC)-α and -β isoforms, induced on day 7 in LoVo cell lines (WT) a significant increased survival when these cells were exposed to increasing doxorubicin concentrations. In contrast, resistant LoVo cell lines (DX) did not show significant changes in the survival to doxorubicin exposure when incubated with the inhibitor of the same specific PKC isoforms. In addition, Gö6976 reduced the PKC-α activity (the main calcium-dependent PKC isoforms expressed) in both cell lines with contemporary increased expression. Under such conditions, an increased nuclear activity and an increased P-glycoprotein expression occurred only in WT-treated cells with respect to untreated cells. Taken together, our data indicate a specific relationship between PKC-α inhibition, the increased nuclear PKC-α activity as well as the increased expression of P-glycoprotein, possibly causing the acquisition of a resistant phenotype in WT LoVo cells.

Keywords: doxorubicin; multidrug resistance; protein kinase C-α

Tumour cells develop drug resistance through multiple mechanisms. One form of drug resistance, termed 'multidrug resistance' (MDR) leads to simultaneous cross-resistance to several structurally unrelated natural products. The mechanism(s) of resistance is due to an energy-dependent drug efflux which results in a net decreased intracellular drug accumulation. Malignant mammalian cell lines with the MDR phenotype may have an amplified mdr-1 gene or an increased protein product of the mdr-1 gene called P-glycoprotein (Fine et al. 1996). Numerous papers demonstrated that MDR was associated with many changes in tumour cells, including increased glutathione peroxidase activity, decreased levels and mutations in DNA topoisomerasers, decreased levels of cytochrome P450 enzymes, overexpression of the anionic isozyme of glutathione-S-transferase, an altered cell membrane composition and changes in the expression and activity of protein kinase C (PKC) isoenzymes (Endicott and Ling. 1989; O’Brian and Ward. 1989).

In human breast cancer cells, phorbol esters increase PKC protein levels as well as the drug resistance in clonogenic assay (Fine et al. 1988). A number of laboratories have reported an increased activity and/or amount of PKC in MDR cell lines such as sarcoma-180 (Posada et al. 1989b), murine fibrosarcoma (Ward and O’Brian. 1991), P-388 leukaemia (Gallapudi et al. 1992), HL-60 leukaemia (Aquino et al. 1988), human KB-carcinoma cells (Posada et al. 1989b) and murine DCF-3F cells (Palayoor et al. 1987). In vitro, P-glycoprotein is phosphorylated by PKC at serine residues (Chambers et al. 1993; Orr et al. 1993).

PKC is a family of at least 11 isotypes which are classified into three groups: c-PKC isoforms: α, β1, βII and γ and n-PKC: ε, δ, η, θ, μ; a-PKC: ζ, λ/ι. Differences in expression, substrate specificity and activator requirements suggest that PKC isoenzymes may have distinct roles in different signalling pathways (Blobel et al. 1996). Little is known about the involvement of specific isoforms in the acquisition of an MDR phenotype. Overexpression of PKC-α induced an increased MDR phenotype in MCF7 cells (Yu et al. 1991). Recently, in acute myelogenous leukaemias showing an MDR phenotype, a positive correlation between PKC-η and -θ expression and MDR phenotype has been demonstrated (Beck et al. 1996).

The aim of the present study was to clarify the role of c-PKC isoforms in the acquisition of a drug-resistant phenotype. We used as a model the well-characterized human colon adenocarcinoma LoVo cell lines sensitive (WT) or resistant (DX) to doxorubicin after continuous exposure to the drug. A previous paper demonstrated that WT and DX cells express mainly the PKC-α isoform. PKC-β showing an activity eightfold lower than PKC-α, PKC-γ being undetectable (Dolfini et al. 1993).

In this study, we demonstrate that long-term inhibition of the PKC-α isoform with Gö6976, a PKC inhibitor specifically selected for α and β PKC isoforms (Figure 1) (Martiny-Baron et al. 1993), treating these cells for 2 hours after plating and 3 days later induced on day 7 in LoVo WT cells a significant increase in survival when exposed to doxorubicin, suggesting a possible involvement of such isoenzyme in the acquisition of a drug-resistant phenotype.
**Table 1** c-PKC activity (pmol per min per 10⁶ cells)

|        | WT       | DX       |
|--------|----------|----------|
|        | Particulate | Cytosol | Particulate | Cytosol |
| G06976 | 68 ± 20  | 32 ± 10  | 27 ± 4     | 8 ± 0.5  |
|        | 27 ± 12**| ND       | 13 ± 5**   | 8 ± 1.0  |

Subconfluent cells were treated with 1 μM G06976 for 2 h and after 3 days. The c-PKC activity was assayed 4 days later. ND = not detected.

**MATERIALS AND METHODS**

**Cell culture**

The human colon adenocarcinoma WT LoVo cell line (American Type Culture Collection, Rockville, USA) was grown in vitro in F12 medium supplemented with 10% fetal calf serum and maintained at 37°C in a humid atmosphere (5% carbon dioxide-95% air). DX LoVo cells were isolated after repeated treatment of such cells with doxorubicin (Grandi et al, 1986).

**Inhibition of PKC isozymes**

Subconfluent cells were treated with 1 μM G06976 (Calbiochem, La Jolla, CA, USA) for 2 h. The medium was removed and fresh medium was added for 24 h. After 3 days, the cells were treated again with 1 μM G06976 for 2 h and fresh medium was added. After 4 days, the cells were detached by trypsinization (Trypsin 0.05%–EDTA 0.02%, Life Technologies) and used for subcellular fractionation or for Western blot analysis.

**Clonogenic surviving test**

Four hundred cells were plated in tissue culture dishes, exposed to 1 μM G06976 for 2 h and then treated with increasing concentrations of doxorubicin for 24 h. Medium was then removed and fresh medium was added. After 3 days, the cells were exposed again to G06976 and 4 days later the surviving colonies, grown in drug-free medium, were counted.

**Subcellular fractionation and PKC assay**

Particulate, cytosolic and nuclear fractions were obtained as previously described (La Porta and Comolli, 1995). Briefly, the cells were homogenized with buffer A containing 20 mM Tris-HCl, pH 7.5, 2 mM EDTA, 0.5 mM EGTA, 5 μM leupeptin, 0.15 μM pepstatin A, 0.5 mM phenylmethylsulphonyl fluoride (PMSF) and centrifuged in a minifuge at 14 000 r.p.m. for 15 min. The supernatant was designated as the cytosolic fraction while the pellet was resuspended in buffer A containing 1% Triton-X100 and finally centrifuged in a minifuge at 14 000 r.p.m. for 15 min. The resulting supernatant was designated as the particulate fraction. Cytosolic and particulate fractions were partially purified on DEAE-Sepharose (Sigma, St. Louis, MO, USA) and PKC was eluted with 120 mM sodium chloride as previously described (La Porta and Comolli, 1995). The nuclear fraction was obtained by homogenizing the cells in buffer B containing 1.3 M sucrose, 1 mM magnesium chloride, 10 mM phosphate buffer, pH 6.8, 1 mM DTT, 10 μg ml⁻¹ leupeptin and 2 mM PMSF and the suspension was layered over 2 ml buffer C solution and centrifuged in a minifuge for 20 min at 14 000 r.p.m. The nuclei were counted and the purity of nuclear preparation was judged by assaying 5'-nucleotidase as a plasma membrane marker and lactate dehydrogenase as a cytosolic marker (La Porta and Comolli, 1995), contamination being less than 2%. Finally, the nuclear extract was obtained from nuclei resuspended in buffer E containing 20 mM Tris-HCl, pH 7.5, 2 mM EDTA, 0.5% Triton-X100, 10 μg ml⁻¹ leupeptin and 2 mM PMSF and sonicated in ice. Total fractions were obtained homogenizing the cells in the buffer A containing 1% Triton-X100.

Particulate, cytosolic and nuclear fractions from murine brain tissue were obtained following the same procedures.

Fractions were tested for c-PKC activity by measuring the amount of ³²P incorporated into histone IIIS from [γ-³²P]ATP in the
presence of phospholipids (phosphatidylerine and diolein) and calcium (Martiny-Baron et al., 1993). Background activity was measured with EGTA and in the absence of phospholipids and calcium.

**Western blot analysis**

Immunoblot analysis was carried out on particulate, cytosolic and total fractions mixed with 2× sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) buffer, then subjected to 10% SDS-PAGE according to Laemmli (Laemmli, 1970) and then transferred to nitrocellulose overnight (Towbin et al., 1979). After blocking non-specific sites with blocking solution provided by Boehringer Mannheim, the sheet was incubated overnight with rabbit polyclonal antibodies (UBI, Lake Placid, NY, USA) recognizing PKC-α isotype or P-glycoprotein and then detected with peroxidase labelled secondary antibody and the chemiluminescent substrate luminal according to the manufacturer’s instructions (BM, Chemiluminescence Western blotting kit, Boehringer Mannheim, Germany). Peptides used to raise the anti-PKC antibodies were used in competition studies to demonstrate specificity of the polyclonal antibodies. The molecular weight of PKC-α was determined using BioRad (Segrate, Italy) standard proteins and were in agreement with those reported by Wetsel et al. (1992). Equal loading of protein on the gel was verified by 10% SDS-PAGE stained with Coomassie brilliant blue R250. Particulate, cytosolic and nuclear fractions obtained from murine brain tissue were used as positive control.

The results were analysed by densitometric analysis using an ImageMaster software (Pharmacia, Uppsala, Sweden).

**RESULTS**

LoVo WT cells continuously exposed to doxorubicin acquire a resistant phenotype (DX), and express higher levels of mdr-1 mRNA encoding for the P-glycoprotein (Grandi et al., 1986). WT and DX LoVo cells express only PKC-α, being PKC-β and -γ undetectable using Western blot analysis (data not shown) according to Beck et al. (1996). To inhibit PKC-α for long periods, at least 7 days, an experimental protocol was considered. We tested different concentrations of Go6976 and we used the lowest concentration able to inhibit significantly PKC-α activity (data not shown). Moreover, with the purpose of reducing the toxicity of the Go6976 and also of maintaining the PKC-α isoform inhibited for long
periods, we treated the cells twice with the inhibitor, once at the beginning of the experiment and the second time at the middle of the treatment on the 3rd day. In fact, under such conditions, the treatment was not too toxic; the LoVo cells that received the complete inhibitory treatment showing at 144 h a slight decrease in the proliferative capacity with respect to untreated cells (Figure 2: WT: 29%, P<0.05; DX: 32%, P < 0.05). A significantly decreased activity in the particulate fraction occurred in both cell lines (Table 1: WT: 60% in treated cells with respect to untreated cells. P<0.01; DX: 52% in treated cells with respect to untreated cells. P < 0.01).

In addition, an increased immunoblot signal for PKC-α was found in treated WT and DX LoVo cells with respect to untreated cells (Figure 3).

Under such conditions, WT cells receiving the complete inhibitory treatment and exposed to increasing concentrations of doxorubicin (from 20 ng ml⁻¹ to 50 ng ml⁻¹) showed an enhanced cell survival with respect to untreated cells (Figure 4). In fact, in spite of the slight inhibition of the proliferative capacity in both cell lines (Figure 2), LoVo WT cells treated with the selective inhibitor G6976 were susceptible to a higher doxorubicin concentration (80 ng ml⁻¹). Moreover, WT-treated cells showed an increased P-glycoprotein expression (Figure 5). In contrast, DX cells treated with the PKC inhibitor did not show significant changes with respect to untreated cells in the survival of doxorubicin exposure (Figure 4), and the level of P-glycoprotein did not show any significant change (data not shown).

We also analysed the nuclear activity and expression of PKC-α, the main PKC isoform expressed in these cells, in both cell lines untreated or treated with G6976. WT-treated cells showed a significant increase (P<0.01) of nuclear PKC-α activity with respect to untreated cells (Figure 6) without changes in its expression (Figure 7). In contrast, no significant nuclear activity and expression was detected in untreated DX cells (Figure 7).

**DISCUSSION**

P-glycoprotein expression is commonly observed in MDR cell lines, including LoVo DX cells (Grandi et al. 1986). Several lines of evidence indicate that PKC regulates the activity and/or the expression of this protein. For example, solid tumours and haemopoietic cell lines treated with phorbol 12-myristate 13-acetate (PMA) or diacylglycerol increased the level of both mdr-1 and P-glycoprotein (Gupta et al. 1994). In general, PKC-α appears the most consistently implicated isoform. In fact, increased expression of such isoenzymes has been reported in a number of cell lines selected for resistance to several anti-cancer agents, including doxorubicin-resistant MCF-7 breast carcinoma cells (Blobe et al. 1993), doxorubicin-, vinblastine- and colchicine-resistant KB human epidermoid carcinoma cells (Davies et al. 1996) and in KB-A10 cell lines (Posada et al. 1989b).

In this report, we have studied the effect of long-term inhibition of the PKC-α isoform on the survival of WT and DX LoVo cells to increasing concentrations of doxorubicin. Treatment with the specific PKC-α and B1 isoforms inhibitor, G6976 (Martiny-Baron et al. 1993), inhibited PKC-α activity, the main PKC isoform expressed in such cells (Drew et al. 1994). However, the treatment with this PKC inhibitor induced an increased expression of PKC-α in both cell lines, suggesting that the enhanced expression of specific PKC isoforms is not always direct evidence of the status of activation of the enzyme. In fact, under our conditions, the cells might compensate for the reduced activity by increasing the level of the enzyme. Moreover, such treatment induced a significant increase in the survival of WT cells exposed to increasing concentrations of doxorubicin and an increased P-glycoprotein expression. In contrast, it did not affect the survival of DX cells that showed basically a higher drug resistance and expressed P-glycoprotein. Therefore, changes in PKC-α activity did not modify the phenotype of such cells. Recently, other authors have studied long-term exposure to staurosporine analogues for 6 months, demonstrating that human lung A549 carcinoma cells acquire a resistant phenotype which does not appear to involve increased drug efflux (Gescher et al. 1997). Our results also indicate the possible involvement of nuclear PKC-α in the acquisition of a drug-resistant phenotype in WT cells. In fact, under these conditions, such isoforms showed an increased activity possibly affecting the expression of P-glycoprotein or of other multidrug-related proteins. In connection with WT LoVo cells, MCF7 cells resistant to doxorubicin showed a nuclear pool of PKC-α that

---

*Figure 6* Nuclear c-PKC activity expressed as pmol per min per 10⁶ nuclei in WT LoVo cells untreated or treated with 1 μM G6976 as described in Figure 1. ***P < 0.001

*Figure 7* Western blot analysis of nuclear c-PKC-α isoform in WT and DX LoVo cells untreated and treated with 1 μM G6976 as described in Figure 1. One hundred micrograms of protein was submitted to 10% SDS-PAGE and then transferred to nitrocellulose sheet overnight. The sheet was incubated with 2.5 μg ml⁻¹ anti-PKC-α antibody. Peptide used to raise the anti-PKC antibody was used in competition studies to demonstrate the specificity of the polyclonal antibody. Nuclear fraction obtained from brain tissue was used as positive control.

---

*British Journal of Cancer (1998) 78(10), 1283–1287 © Cancer Research Campaign 1998*
probably maintained the drug resistant state of these cells (Lee et al. 1992). In contrast, in DX cell lines we did not find any significant expression of such isoforms in the nucleus. c-PKC-α showing a different subcellular distribution in DX LoVo with respect to MCF-7 cell lines. Recently, other specific PKC inhibitors such as bisindolylmaleimide and calphostin C blocked the activation of NF-κB, suggesting a relationship between PKC activation and NF-κB activation that might contribute to the expression of genes involved in the resistant phenotype (Das and White. 1997). In addition, the modulation of other kinases downstream with respect to PKC-α might be involved in the acquisition of the resistant phenotype of LoVo WT cells.

Taken together, our results indicate a relationship between PKC-α inhibition, an increased nuclear activity of this isoform and the acquisition of a resistant phenotype in LoVo WT cells. It is tempting to speculate that overexpression of c-PKC-α and the long-term inhibition of such isoforms induce a resistant phenotype possibly through different mechanisms. In the first case, the permanent high level of c-PKC-α is likely to induce the phosphorylation of P-glycoprotein, whereas in the second case the long-term inhibition enhances the P-glycoprotein level. Therefore, the hypothesis speculated by several authors that the selective inhibition of PKC-α may chemosensitize tumour cells to anti-cancer therapy might not be correct. Recently, different concentrations of doxorubicin induced apoptosis or oxidative DNA damage (Muller et al. 1997). Work is in progress to analyse the intracellular role of PKC-α with respect to the cytotoxic mechanism of doxorubicin under the present conditions and also in other human cell lines.

ACKNOWLEDGEMENTS

This work was supported by a grant from the Ministero della Ricerca Scientifica e Tecnologica (MURST, 40%). We are grateful to Miss U Malgeri for her skilful technical assistance.

REFERENCES

Aquino A. Hartman KD, Knobe MC, Grant S, Huang KP, Niu CH and Glazer RI (1988) Role of protein kinase C in phosphorylation of vinculin in adriamycin-resistant HL-60 leukemia cells. Cancer Res 48: 3324–3329

Beck J, Handgretinger R, Klingebiel T, Dopfer R, Schaich M, Ehninger G, Niethammer D and Gekele V (1996) Expression of PKC isoforms and MDR-associated genes in primary and relapsed state AML. Leukemia 10: 426–433

Blöge GC, Sachs CW, Kanh WA, Fabbro D, Stabel S, Wessell WC, Obeid LM, Fine RL and Hannun YA (1993) Selective regulation of expression of protein kinase C (PKC) isoforms in multidrug-resistant MCF-7 cells. J Biol Chem 268: 658–664

Blöge GC, Sibling S, Obeid LM and Hannun YA (1996). Protein kinase C isoforms: regulation and function. Cancer Surveys 27: 213–246

Chambers TC, Pohl I, Raynor RL and Kuo JK (1993) Identification of specific sites in human P-glycoprotein phosphorylated by protein kinase C. J Biol Chem 268: 4592–4595

Das KC and White CW (1997) Activation of NF-κB by antineoplastic agents. J Biol Chem 272: 14914–14920

Davies R, Budworth J, Riley J, Snowden R, Gescher A and Gant TW (1996) Regulation of P-glycoprotein 1 and 2 gene expression and protein activity in two MCF-7/DX cell line subclones. Br J Cancer 73: 307–315

Dolfini E, Dadisa T, Perletti GP, Romagnoni M and Piccinini F (1993) Analysis of calcium-dependent protein kinase-C isoenzymes in intrinsically resistant cloned lines of LoVo cells: reversal of resistance by kinase inhibitor 1-5-isooctanoyloxy-2-methilpyperazine. Anticancer Res 13: 1123–1128

Drew L, Grove N, Hallam TJ, Warr R and Rumsby MG (1994) Changes in protein kinase C subspecies protein expression and activity in a series of multidrug-resistant human KB carcinoma cell lines. Oncol Res 9: 429–438

Endicott JA and Ling V (1989) The biochemistry of P-glycoprotein-mediated multidrug resistance. Ann Rev Biochem 58: 137–171

Fine RL, Patel J and Chabner BA (1988) Phorbol esters induce multidrug resistance in breast cancer cells. Proc Natl Acad Sci USA 85: 582–586

Fine RL, Chambers TC and Sachs CW (1996) P-glycoprotein, multidrug resistance and protein kinase C. Stem Cells 14: 47–55

Gallapodi S, Patel K, Jain V and Gupta S (1992) Protein kinase C isoforms in multidrug resistant P388/ADR cells: a possible role in daunorubicin transport. Cancer Lett 62: 69–75

Gescher A, Courage C, Brädder S, Jones T and Schultz-Mosgau M-H (1997) The staurosporine analogs LCNU-01 and CGP 41251 induce drug resistance in A549 lung carcinoma cells (abstract). Proc Am Assoc Cancer Res 38: 590

Grandi M, Geroci C and Giuliani FC (1986) Isolation and characterization of a human colon adenocarcinoma cell line resistant to doxorubicin. Br J Cancer 54: 515–518

Gupta S, Patel K, Hingh H and Gallapodi S (1994) Effect of calphostin (PKC inhibitor) on doxorubicin resistance in P388/ADR and HL-60/AR cells: reversal of drug resistance possibly via P-glycoprotein. Cancer Lett 57: 104–110

Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680–685

La Porta CAM and Comollini R (1995) Over-expression of protein kinase C δ is associated with a delay in preneoplastic lesion development in diethylstilbestrol-induced rat hepatocarcinogenesis. Carcinogenesis 16: 1253–1258

Lee SA, Karaszewicz JW and Anderson WB (1992) Elevated level of nuclear protein kinase C in multidrug-resistant MCF-7 human breast carcinoma cells. Cancer Res 52: 3750–3759

Martiny-Baron G, Kazanietz MG, Mishak H, Blumberg PM, Koch G, Marme’ D and Schachtele C (1993) Selective inhibition of protein kinase C isoforms by the indolocarbazole Go6976. J Biol Chem 268: 9194–9197

Muller I, Janner A, Bruchel T, Niethammer D and Hallwell B (1997) Effect of concentrations on the cytotoxic mechanism of doxorubicin-apoptosis and oxidative DNA damage. Biochem Biophys Res Commun 230: 254–257

O’Brien C and Ward N (1989) Biology of the protein kinase family. Cancer Met Rev 8: 199–214

 Orr GA, Han EKH, Browse PC, Nieves E, O’Connor BM, Yang CP and Horowisz SB (1993) Identification of the major phosphorylation domain of murine mdr 1b P-glycoprotein. J Biol Chem 268: 25054–25062

Palayoor ST, Stein IM and Hatt WN (1987) Inhibition of protein kinase C by antineoplastic agents: implication for drug resistance. Biochem Biophys Res Commun 148: 718–725

Posada J, Vicki P and Tritton TR (1989a) Protein kinase C in adriamycin action and resistance in mouse sarcoma 180 cells. Cancer Res 49: 6634–6639

Posada JA, McKeegan EM, Worthington KF, Morin MJ, Jaken S and Tritton TR (1998b) Human multidrug resistant KB cells overexpress protein kinase C involvement in drug resistance. Cancer Commun 1: 265–267

Towbin H, Staehlin T and Gordon J (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets. Proc Natl Acad Sci USA 76: 4350–4354

Yu G, Ahmad S, Aquino A, Fairchild CR, Trepel JB, Otomo S, Suzuki K, Tsuruo T, Cowan KH and Glazer RI (1991) Transfection with protein kinase C α confers increased multidrug resistance to MCF-7 cells expressing P-glycoprotein. Cancer Commun 3: 181–189

Ward NE and O’Brian CA (1991) Distinct patterns of phorbol ester-induced downregulation of protein kinase C activity in adriamycin-selected multidrug resistant and parental murine fibrosarcoma cells. Cancer Lett 58: 189–193

Wessell WC, Khan WA, Merchenthaler L, Rivera H, Halphen AE, Phung HM, Nagro Vilar A and Hannun YA (1992) Tissue and cellular distribution of the extended family of protein kinase C isoenzymes. J Cell Biol 117: 121–133